Investor Relations

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area of oncology with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has promising product candidates in clinical and late preclinical development and has entered into strategic collaborations with leading global pharmaceutical companies.

Recent News > MORE

Date Title and Summary
Toggle Summary Five Prime Therapeutics Announces Second Quarter 2018 Financial Results
Cabiralizumab continues to advance in randomized Phase 2 trial in pancreatic cancer Bemarituzumab has advanced through Phase 1 safety lead-in of Phase 1/3 FIGHT global trial in gastric cancer; preparation for Phase 3 portion underway Four product candidates in the clinic, fifth planned by end of
Toggle Summary Five Prime Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 8
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 26, 2018-- Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2018 financial results

Upcoming and Recent Events > MORE

Date Event Details
Summary Toggle Wednesday, August 08, 2018 4:30 PM EDT
Summary Toggle Thursday, June 14, 2018 8:00 AM PDT
Summary Toggle Thursday, June 07, 2018 11:00 AM EDT


Francis Sarena
Chief Strategy Officer and Secretary

Supporting Materials